Operating

Acquired in-process research and development

Biogen Acquired in-process research and development remained flat by 0.0% to $21.25M in Q4 2025 compared to the prior quarter.

Analysis

StatementCash Flow Statement
SectionOperating
First reportedQ1 2023
Last reportedQ4 2025Feb 6, 2026
Metric ID: operating_research_and_development_asset_acquired_other__65ec84

Historical Data

3 years
 FY'23FY'24FY'25
Value$0.00$0.00$85.00M
Range$0.00 – $85.00M

Acquired in-process research and development at Other Companies

Eli Lilly logo
Eli LillyLLYView metric
AbbVie logo
AbbVieABBVView metric
Gilead Sciences logo
Gilead SciencesGILDView metric
Merck & Co. logo
Merck & Co.MRKView metric

Frequently Asked Questions

What is Biogen's acquired in-process research and development?
Biogen (BIIB) reported acquired in-process research and development of $21.25M in Q4 2025.